Edition:
United States

Urogen Pharma Ltd (URGN.OQ)

URGN.OQ on NASDAQ Stock Exchange Global Market

37.94USD
15 Dec 2017
Change (% chg)

$0.84 (+2.26%)
Prev Close
$37.10
Open
$37.28
Day's High
$38.00
Day's Low
$37.25
Volume
46,507
Avg. Vol
28,950
52-wk High
$44.38
52-wk Low
$13.01

Latest Key Developments (Source: Significant Developments)

Urogen Pharma Q3 loss per share $0.02
Tuesday, 14 Nov 2017 07:00am EST 

Nov 14 (Reuters) - Urogen Pharma Ltd :Urogen Pharma reports third quarter 2017 financial results and recent corporate developments.Q3 loss per share $0.02.Q3 earnings per share view $-0.05 -- Thomson Reuters I/B/E/S.  Full Article

Menora Mivtachim reports 5.38 pct passive stake in UroGen Pharma ‍​
Wednesday, 8 Nov 2017 09:02am EST 

Nov 8 (Reuters) - UroGen Pharma Ltd -:Menora Mivtachim Holdings Ltd reports 5.38 percent passive stake in UroGen Pharma Ltd as of Nov 1 - SEC filing ‍​.  Full Article

Urogen Pharma receives FDA fast track designation for Mitogel
Tuesday, 29 Aug 2017 08:30am EDT 

Aug 29 (Reuters) - Urogen Pharma Ltd :Urogen Pharma receives FDA fast track designation for Mitogel for the treatment of upper tract urothelial carcinoma (UTUC).Mitogel currently being evaluated in ongoing pivotal phase 3 olympus clinical trial in patients with low-grade UTUC.  Full Article

UroGen Pharma Q2 loss per share $0.70
Monday, 14 Aug 2017 04:05pm EDT 

Aug 14 (Reuters) - Urogen Pharma Ltd :UroGen Pharma reports second quarter 2017 financial results and recent corporate developments.Q2 loss per share $0.70.Q2 earnings per share view $-0.57 -- Thomson Reuters I/B/E/S.  Full Article

Jay Moorin reports a 11.5 pct passive stake in Urogen Pharma
Thursday, 20 Jul 2017 04:55pm EDT 

July 20 (Reuters) - Urogen Pharma Ltd :Jay Moorin reports a 11.5 percent passive stake in Urogen Pharma Ltd as of May 9, 2017 - SEC filing.  Full Article

Allergan submits investigational NDA for rtgel in combination with botox
Wednesday, 19 Jul 2017 08:30am EDT 

July 19 (Reuters) - Urogen Pharma Ltd ::Investigational new drug application for rtgel™ in combination with botox® for the treatment of overactive bladder submitted to FDA by Allergan.Says it will receive a milestone payment of $7.5 million under its exclusive worldwide licensing agreement with allergan.Urogen Pharma - milestone payment resulting from Allergan's submission of investigational new drug application for rtgel in combination with botox to U.S. FDA.  Full Article

Arkin Communications reports 13.32 pct stake in Urogen Pharma Ltd as on May 4, 2017
Tuesday, 30 May 2017 08:58am EDT 

May 30 (Reuters) - Arkin Communications Ltd: :Arkin Communications Ltd reports a 13.32 percent stake in Urogen Pharma Ltd as on May 4, 2017 - sec filing.  Full Article

Urogen Pharma says initial public offering of 4.47 mln common shares priced at $13 per share
Wednesday, 3 May 2017 05:55pm EDT 

May 3 (Reuters) - Urogen Pharma Ltd :Urogen Pharma announces pricing of initial public offering.Says initial public offering of 4.47 million common shares priced at $13.00per share.  Full Article

BRIEF-Urogen Pharma Q3 loss per share $0.02

* Urogen Pharma reports third quarter 2017 financial results and recent corporate developments